Qol Holdings (3034) Fundamentals 2026 — P/E 10.6x, Revenue Analysis | SniperIQ
Qol Holdings (3034) is a JP-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥78.5B, trading at ¥2090.00 on the JPX. This SniperIQ fundamentals page covers Qol Holdings's valuation (P/E 10.6x, P/B 1.4x), profitability (net margin 2.5%), revenue (¥290.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Qol Holdings's market cap?
Qol Holdings (3034) has a market capitalization of approximately ¥78.5B, trading at ¥2090.00 on the JPX. Market cap moves with the live share price.
What is Qol Holdings's P/E ratio?
Qol Holdings's trailing twelve-month P/E ratio is 10.6x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Qol Holdings?
Qol Holdings runs a net profit margin of 2.5%, a gross margin of 12.6%, and an operating margin of 5.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Qol Holdings generate?
Qol Holdings reported revenue of ¥290.8B for fiscal year 2025, with net income of ¥7.4B and earnings per share (EPS) of 197.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Qol Holdings pay a dividend?
Qol Holdings offers a trailing dividend yield of about 2.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Qol Holdings financially healthy?
Qol Holdings carries a debt-to-equity ratio of 0.65x and a current ratio of 0.78x, with a market beta of -0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Qol Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Qol Holdings (3034) the key facts are: market cap ¥78.5B, P/E 10.6x, revenue ¥290.8B, 52-week range 1681-2404. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Qol Holdings's full fundamentals live
Get Qol Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.